(Reuters) - French vaccine maker Valneva shares gained around 20% on Thursday, as trading resumed hours after Britain approved its inactivated COVID-19 vaccine.
The stock is on course for its best day since January 20, when it said early studies showed the vaccine was effective against the Omicron variant.